Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, Naples, Italy; CEINGE - Biotecnologie avanzate, Naples, Italy.
Dipartimento di Scienze Mediche Traslazionali, Università di Napoli Federico II, Naples, Italy.
J Cyst Fibros. 2021 Jan;20(1):e1-e6. doi: 10.1016/j.jcf.2020.06.015. Epub 2020 Jun 23.
Cystic fibrosis (CF) patients have reduced intestinal absorption of sterols and, despite enhanced endogenous synthesis, low plasma cholesterol. Lumacaftor/ivacaftor CFTR protein modulator therapy is used to improve the clinical outcome of CF patients homozygous for F508del mutation (homo-deltaF508). Aim of the study is to evaluate the cholesterol metabolism and hepatobiliary injury/function in adult homo-deltaF508 patients, before and after lumacaftor/ivacaftor treatment. Baseline parameters in homo-deltaF508 patients were compared to those in CF patients compound heterozygous for F508del mutation and another severe mutation (hetero-deltaF508).
Cholesterol metabolism was evaluated measuring plasma phytosterols and cholestanol, as intestinal absorption markers, and lathosterol, as liver biosynthesis marker. We quantified serum vitamin E, as nutritional marker. We evaluated liver injury by aspartate aminotransferase (AST) and alanine transaminase (ALT), biliary injury by γ-glutamyltransferase (γGT) and AP, and the liver function by bilirubin and albumin.
Before the treatment, homo-deltaF508 patients (n = 20) had significantly lower cholesterol and vitamin E compared to hetero-deltaF508 (n = 20). Lumacaftor/ivacaftor treatment caused: 1) further reduction of cholesterol; 2) lathosterol reduction, suggesting a normalization of endogenous synthesis; 3) cholestanol and vitamin E increment, indicating an improvement of lipid digestion/absorption. Vitamin E difference (after-before treatment) was positively associated to treatment months. Alkaline phosphatase was also reduced.
These data suggest an effect of lumacaftor/ivacaftor on cholesterol metabolism and enterohepatic flux in CF patients. However, lumacaftor/ivacaftor does not promote the increase of cholesterol serum concentration that on the contrary declines. Further studies are needed to research the real mechanism causing this reduction.
囊性纤维化(CF)患者的固醇肠吸收减少,尽管内源性合成增强,但血浆胆固醇水平较低。利那洛肽/依伐卡托 CFTR 蛋白调节剂治疗用于改善纯合 F508del 突变(纯合 -DeltaF508)CF 患者的临床结局。本研究旨在评估利那洛肽/依伐卡托治疗前后纯合 -DeltaF508 患者的胆固醇代谢和肝胆损伤/功能。将纯合 -DeltaF508 患者的基线参数与 F508del 突变和另一种严重突变(杂合 -DeltaF508)复合杂合的 CF 患者进行比较。
通过测量血浆植物固醇和胆甾烷醇作为肠道吸收标志物,以及羊毛甾醇作为肝脏生物合成标志物,评估胆固醇代谢。我们量化了血清维生素 E 作为营养标志物。我们通过天门冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)评估肝损伤,通过 γ-谷氨酰转移酶(γGT)和碱性磷酸酶(AP)评估胆汁淤积损伤,并通过胆红素和白蛋白评估肝功能。
在治疗前,与杂合 -DeltaF508 患者(n=20)相比,纯合 -DeltaF508 患者(n=20)的胆固醇和维生素 E 水平显著降低。利那洛肽/依伐卡托治疗导致:1)胆固醇进一步降低;2)羊毛甾醇减少,提示内源性合成正常化;3)胆甾烷醇和维生素 E 增加,表明脂质消化/吸收改善。维生素 E 的差值(治疗前后)与治疗月数呈正相关。碱性磷酸酶也降低了。
这些数据表明利那洛肽/依伐卡托对 CF 患者的胆固醇代谢和肠肝循环有影响。然而,利那洛肽/依伐卡托并没有促进胆固醇血清浓度的增加,反而使其降低。需要进一步研究以研究导致这种减少的真正机制。